40 results about "Benzylpiperazine" patented technology

The invention discloses a novel 4-(2-(pyrrolidine / piperidine-1-yl)benzyl)-piperazine urea type TRPV1 antagonist and a preparation method and application thereof. The invention relates to a compound ina general formula (I) and a pharmaceutically acceptable salt thereof, in the formula, n is equal to 1 or 2, R is H, F, Cl, Br, I, CF3, CH3 or OH, and Ar is phenyl or aromatic heterocyclic group. Thecompounds have a strong analgesic effect, the activity of part of the compounds is far higher than that of a TRPV1 receptor antagonist BCTC, almost no body temperature rise side effect exists, and theinvention further relates to the preparation method of the compounds and pharmaceutical preparations containing the compounds.

The invention belongs to the technical field of pharmacy, particularly discloses a benzylpiperazine urea TRPV1 antagonistic and MOR agonistic double-target drug as well as a preparation method and application thereof, and particularly relates to a compound in a general formula (I) and pharmaceutically acceptable salts thereof, and the drug can be used for preventing and / or treating diseases related to TRPV1 and / or MOR activity, such as pain, inflammation, immune dysfunction, neurological and psychiatric disorders, respiratory diseases, urinary and reproductive disorders. the invention also relates to a preparation method of the compounds and a pharmaceutical preparation containing the compounds.

Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg / day-130 mg / day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.

Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.)

Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.)

The invention discloses a method for preparing saturated potassium azacyclo-trifluoroborates, which comprises the following steps: 1. reacting pyrrolidine and piperidine used as initial raw materials and tert-butyl carbonic anhydride to generate N-tert-butyl carbonyl pyrrolidine and N-tert-butyl carbonyl piperidine, and performing heating reflux on the N-tert-butyl carbonyl piperazine used as an initial raw material and benzyl chloride to generate N-tert-butyl carbonyl-4-benzyl piperazine; and 2. by means of the orientation effect of the N-tert-butyl carbonyl, in a nitrogen protective atmosphere, reacting with sec-butyl lithium at low temperature, then reacting with trimethylborate to generate saturated o-boric acid, adding a saturated KHF2 solution without separating the boric acid, and performing post treatment to respectively generate a potassium N-tert-butyl carbonyl-2-pyrrolidine trifluoroborate, a potassium N-tert-butyl carbonyl-2-piperidine trifluoroborate and a potassium N-tert-butyl carbonyl-4-benzyl-2-piperazine trifluoroborate. These saturated potassium azacyclo-trifluoroborates prepared by the invention are all white solids, are stable at room temperature in an air atmosphere, belong to very important organic chemical reagents and medical intermediate compounds, and have wide application prospects. The method disclosed by the invention is simple to operate, utilizes the cheap and accessible initial raw materials, achieves high yield and favorable purity, is easy to implement scale-up production, and realizes commercialized production.

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

The invention relates to novel camptothecin 7-piperazinyl thiocarbamide compounds disclosed as Formula (I), a preparation method of the compounds, and application of the compounds in preparing antineoplastic drugs. The chemical general formula of the compounds is disclosed as Figure (I). The preparation method of the compounds disclosed as Formula (I) comprises the following step: carrying out reaction on 7-benzylpiperazinyl-camptothecin and alkyl / aryl isorhodanate. The cytotoxic activity test proves that the compounds have favorable antineoplastic activity, and part of the compounds have higher activity than the clinical drug irinotecan; and the compounds can be used for preparing antineoplastic drugs. The preparation method has the advantages of simple preparation technique, cheap and accessible raw materials and high product purity.

The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.

Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.)

The invention discloses a camptothecin sulfonyl amidine compound and a preparation method and application thereof. The camptothecin sulfonyl amidine compound is shown in the formula 1, wherein in the formula, R1 is any one of methyl, ethyl, p-chlorophenyl, p-nitrophenyl, p-methylphenyl, p-fluorophenyl, phenyl, thienyl, pyridyl and naphthyl; R2 is any one of hydrogen, fluorine and methoxy. The preparation method of the camptothecin sulfonyl amidine compound includes the steps that 7-benzylpiperazine-camptothecin trifluoroacetate is dissolved into methylene dichloride, a catalyst (triethylamine) is added for stirring to clarify a solvent, then a sulfonyl azide and alkyne are sequentially added, finally, copper iodide is added for a catalytic reaction, after completion, methylene dichloride is used for a quenching reaction, then the solvent is removed, and a crude product of the target product is obtained. The camptothecin sulfonyl amidine compound can be applied to preparation of medicine for treating all kinds of cancers.

Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg / day-130 mg / day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.

The invention discloses a camptothecin sulfonyl amidine compound and a preparation method and application thereof. The camptothecin sulfonyl amidine compound is shown in the formula 1, wherein in the formula, R1 is any one of methyl, ethyl, p-chlorophenyl, p-nitrophenyl, p-methylphenyl, p-fluorophenyl, phenyl, thienyl, pyridyl and naphthyl; R2 is any one of hydrogen, fluorine and methoxy. The preparation method of the camptothecin sulfonyl amidine compound includes the steps that 7-benzylpiperazine-camptothecin trifluoroacetate is dissolved into methylene dichloride, a catalyst (triethylamine) is added for stirring to clarify a solvent, then a sulfonyl azide and alkyne are sequentially added, finally, copper iodide is added for a catalytic reaction, after completion, methylene dichloride is used for a quenching reaction, then the solvent is removed, and a crude product of the target product is obtained. The camptothecin sulfonyl amidine compound can be applied to preparation of medicine for treating all kinds of cancers.

The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.

The invention discloses a substitutive (S)-benaldehyde sulfonyl pyrrolidine-3-amino derivative, and a preparation method and application thereof. The structure of the compound is shown in an equation I. The preparation method includes: different substitutive alpha-toluenesulfonyl chloride and (S)-3-tert-butoxycarbonyl amino pyrrolidine are reacted, deprotection of a reaction product is performed so that an important intermediate is generated; and another intermediate can be prepared from different substitutive benzylpiperazine via 2-chloromethylation. The two intermediates are reacted in tetrahydrofuran in a backflow manner overnight, and the structure as shown in the equation I can be obtained by thin layer chromatography. A compound has an excellent tumor activity inhibiting effect, and has important practical value and application prospect in the field of preparation of anti-tumor medicines.

The invention discloses a 6-phenylimidazol[2, 1-b]thiazole-3-amide derivative, its preparation method and application. The structural formula of the compound is shown as formula I, wherein R1 is H, or one or more of the following mono-substituted or multi-substituted groups on a benzene ring: fluorine, chlorine, bromine, methyl, methoxyl, hydroxyl, nitro, amino, trifluoromethyl and cyano; R2 is hydrogen, fluorine, chlorine, bromine, methyl, methoxyl, hydroxyl, mercapto, amino, methylamino, ethylamino, morpholine, piperazine, methyl piperazine, ethyl piperazine, benzyl piperazine, p-methoxylbenzyl piperazine or p-chlorobenzyl piperazine; and n is 0 or 1 or 2. The raw materials for preparation of the derivative are easily available, the reaction is simple, and the synthesis steps are simple and are easy to operate. The compound provided in the invention has good anti-tumor activity, and has important practical value and application prospects in the field of antitumor medicine preparation. (Formula I).

Disclosed are benzylpiperazinyl-indolinylethanone compounds which are useful for the treatment and / or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABA.sub.A receptors in tissue samples.

The invention discloses the application of a genistein benzylpiperazine derivative in the field of diabetes, wherein the molecular formula of the genistein benzylpiperazine derivative is: C 27 h 28 N 2 o 5 ; Molecular weight: 460.52; Name: 8‑((4‑(2,4‑dimethoxyphenyl)piperazin‑1‑yl)methyl)‑5,7‑dihydroxy‑3‑(4‑hydroxy phenyl)-4H-benzopyran-4-one. It has the effect of significantly reducing fasting blood sugar by activating AMPK and inhibiting NF-κB pathway, so this derivative can be used in the field of diabetes.

Disclosed are compounds of the formula:or the pharmaceutically acceptable addition salts thereof wherein:R1 is halogen or C1–C4 alkyl; andR2 and R3 are the same or different and represent hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, alkylthio, hydroxy, amino, mono(C1–C4)alkylamino, di(C1–C4)alkylamino, orR2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety,which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

The invention relates to the field of medicinal chemistry, in particular to a benzylpiperazine compound (I) with anti-inflammatory activity and a preparation method thereof; pharmacodynamic tests prove that the compound provided by the invention has a COX-2, NF-[kappa]B and p38 MAPK multi-target inhibition effect, so that the compound can be used for preventing and treating inflammation-related diseases.

The invention belongs to the technical field of fluorescent probes, and particularly relates to a 1, 8-naphthalimide derivative and application. The invention discloses application of 3-[6-(4-benzyl piperazine-1-yl)-1, 3-dioxo-1H-benzo [iso] quinoline-2 (3H)-yl] propionic acid in preparation of a fluorescent probe for detecting intracellular pH, and application in cell imaging. The derivative is excited at 402nm in an aqueous solution, and has maximum emission at 526nm. In a phosphate buffer system, the fluorescence intensity at 526nm is gradually enhanced along with the reduction of the pH value from 9.00 to 4.00. The pKa value is 6.69, and the pH linear range is 6.40 to 8.00. Besides, the probe has good selectivity, water solubility and low toxicity, is suitable for detecting the pH change of a water environment, and can be used for detecting the pH change in cells by utilizing a laser confocal microscopy imaging technology.

The invention belongs to the field of medicines and particularly relates to the use of 1-erucic acyl-4-(3'-chloro-)benzylpiperazine in medicine of inhibition of vascular endothelial cell oxidative stress, inflammation and adhesion. The concrete structure of the compound is shown in the description. 1-erucic acyl-4-(3'-chloro-)benzylpiperazine has obvious effects on inhibiting oxidant stress generated by vascular endothelial cells and monocyte and adhering action and inflammation generating effect of the vascular endothelial cells, and can be used for preparing medicines for treating vascular diseases.

The invention belongs to the field of medicines and particularly relates to the use of 1-erucic acyl-4-(3'-chloro-)benzylpiperazine in medicine of inhibition of vascular endothelial cell oxidative stress, inflammation and adhesion. The concrete structure of the compound is shown in the description. 1-erucic acyl-4-(3'-chloro-)benzylpiperazine has obvious effects on inhibiting oxidant stress generated by vascular endothelial cells and monocyte and adhering action and inflammation generating effect of the vascular endothelial cells, and can be used for preparing medicines for treating vascular diseases.

The invention belongs to the technical field of fluorescent probes, and particularly relates to a 1, 8-naphthalimide derivative and application. The invention discloses application of 3-[6-(4-benzyl piperazine-1-yl)-1, 3-dioxo-1H-benzo [iso] quinoline-2 (3H)-yl] propionic acid in preparation of a fluorescent probe for detecting intracellular pH, and application in cell imaging. The derivative is excited at 402nm in an aqueous solution, and has maximum emission at 526nm. In a phosphate buffer system, the fluorescence intensity at 526nm is gradually enhanced along with the reduction of the pH value from 9.00 to 4.00. The pKa value is 6.69, and the pH linear range is 6.40 to 8.00. Besides, the probe has good selectivity, water solubility and low toxicity, is suitable for detecting the pH change of a water environment, and can be used for detecting the pH change in cells by utilizing a laser confocal microscopy imaging technology.

Disclosed is the use of a PAR-1 antagonist, in particular selected from vorapaxar, atopaxar and 3-2-(chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazine-1-yl]propenone, for the prevention and / or treatment of a chronic inflammatory disease of the intestine and of the colon in a mammal, in particular Crohn's disease.

The invention discloses an application of a genistein benzyl piperazine derivative in the diabetes field. The molecular formula of the genistein benzyl piperazine derivative is C27H28N2O5; the molecular weight of the genistein benzyl piperazine derivative is 460.52; and the name of the genistein benzyl piperazine derivative is 8-((4-(2,4-dimethoxyphenyl)piperazine-1-yl)methyl)-5,7-dyhydroxyl-3-(4-hydroxyphenyl)-4H-benzopyran-4-one. The genistein benzyl piperazine derivative can remarkably reduce the fasting blood glucose level by activating AMPK and inhibiting the NF-kappa B pathway, so as tobe applicable to the diabetes field.

The invention belongs to the technical field of medicine, and relates to 2-[(pyridyl-2-yl methyl)thio]-1H-benzimidazole compounds, a preparation method thereof and application of the compounds in preparation of drugs for antitumor diseases. The structural general formula of the 2-[(pyridyl-2-yl methyl)thio]-1H-benzimidazole compounds and prodrugs, pharmaceutically active metabolites and pharmaceutically acceptable salts of the 2-[(pyridyl-2-yl methyl)thio]-1H-benzimidazole compounds are shown in the description, wherein R1 and R2 are the same or different, and are selected from hydrogen, C3-C6cycloalkyl groups, phenyl groups, halogen-substituted phenyl groups, C1-C4 alkoxy-substituted phenyl groups, phenyl groups with simultaneous substitution of halogen and C1-C4 alkoxy groups and benzylgroups, or substituted or unsubstituted phenylpiperazinyl, benzylpiperazinyl or diphenylmethylpiperazinyl groups are formed by R1, R2 and nitrogen atoms attached to R1 and R2; and the substituent groups comprise C1-C4 alkyl groups, C1-C4 alkoxy groups and halogen, and R3 and R5 can be selected from H and C1-C4 alkyl groups. The synthesis method of the compounds is simple and convenient, and is suitable for industrial production, and it is shown by biological activity tests that the compounds have antitumor activity, and are novel antitumor drugs.

The invention discloses a preparation method of an imatinib impurity. The preparation method comprises: using 1,4-bi(4-carboxybenzyl)piperazine as a raw material, and at presence of N,N- diisopropylcarbodiimide, 1-hydroxy benzotriazole and N,N-diisopropylethylamine, reacting with imaamine to obtain the imatinib impurity 1,4-bi[4-[4-methyl-3-[[4-(pyridine-3-group)pyrimidyl-2group]amino]phenyl]carbamoyl radical]benzyl piperazine. The preparation method provided by the invention is simple, low in requirement on reaction conditions, high in product purity, high in yield, and suitable for industrial production. The synthesized impurity can be used for qualitative and quantitative analysis of the impurity, thus improving drug safety of the imatinib.